ATE327750T1 - Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung - Google Patents

Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung

Info

Publication number
ATE327750T1
ATE327750T1 AT02701418T AT02701418T ATE327750T1 AT E327750 T1 ATE327750 T1 AT E327750T1 AT 02701418 T AT02701418 T AT 02701418T AT 02701418 T AT02701418 T AT 02701418T AT E327750 T1 ATE327750 T1 AT E327750T1
Authority
AT
Austria
Prior art keywords
benz
prodrugs
indole
benzo
tumor treatment
Prior art date
Application number
AT02701418T
Other languages
German (de)
English (en)
Inventor
Mark Searcey
Laurence Patterson
Original Assignee
Univ London Pharmacy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London Pharmacy filed Critical Univ London Pharmacy
Application granted granted Critical
Publication of ATE327750T1 publication Critical patent/ATE327750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02701418T 2001-02-22 2002-02-22 Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung ATE327750T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01301634 2001-02-22

Publications (1)

Publication Number Publication Date
ATE327750T1 true ATE327750T1 (de) 2006-06-15

Family

ID=8181736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02701418T ATE327750T1 (de) 2001-02-22 2002-02-22 Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung

Country Status (6)

Country Link
US (2) US7192977B2 (cg-RX-API-DMAC10.html)
EP (1) EP1408960B1 (cg-RX-API-DMAC10.html)
JP (1) JP4862120B2 (cg-RX-API-DMAC10.html)
AT (1) ATE327750T1 (cg-RX-API-DMAC10.html)
DE (1) DE60211905T2 (cg-RX-API-DMAC10.html)
WO (1) WO2002067930A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
NZ536107A (en) * 2004-10-22 2007-06-29 Auckland Uniservices Ltd Nitrobenzindoles and their use in cancer therapy
GB0505644D0 (en) 2005-03-18 2005-04-27 Univ London Pharmacy Analogues of the azinomycins as anti-tumour agents and as prodrugs
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
HUE035798T2 (en) * 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
NO3056203T3 (cg-RX-API-DMAC10.html) 2010-04-21 2018-05-12
TR201810856T4 (tr) 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
DK2948184T3 (en) 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv Duocarmycin-ADCs with improved in vivo antitumor activity
WO2015104373A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
CN109020820B (zh) * 2017-06-08 2021-06-25 杭州惠诺医药科技有限公司 一种6-溴-2-氨基萘的制备方法
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN113292554A (zh) * 2021-06-25 2021-08-24 守恒(厦门)医疗科技有限公司 二氢萘并[2,1-d]异噁唑酰胺类衍生物及其在抗肿瘤药物的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413132A (en) 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
GB9519490D0 (en) 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
JPH11513391A (ja) * 1995-10-03 1999-11-16 ザ スクリップス リサーチ インスティテュート Ｃｃ−１０６５ 及びズオカーマイシンのｃｂｉ 類縁体
US5985908A (en) * 1996-03-08 1999-11-16 The Scripps Research Institute MCBI analogs of CC-1065 and the duocarmycins
US5843937A (en) 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
CA2255703A1 (en) * 1996-05-31 1997-12-04 Dale L. Boger Analogs of cc-1065 and the duocarmycins
ATE310725T1 (de) * 1996-09-12 2005-12-15 Auckland Uniservices Ltd Kondensierte n-acylindole als antitumormittel
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
US7626026B2 (en) * 2001-02-22 2009-12-01 University Of Bradford Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
US7179921B2 (en) * 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
US20050026987A1 (en) * 2003-05-13 2005-02-03 The Scripps Research Institute CBI analogues of the duocarmycins and CC-1065
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor

Also Published As

Publication number Publication date
WO2002067930A1 (en) 2002-09-06
JP2004522779A (ja) 2004-07-29
US7192977B2 (en) 2007-03-20
EP1408960B1 (en) 2006-05-31
DE60211905T2 (de) 2007-01-18
US8017640B2 (en) 2011-09-13
DE60211905D1 (de) 2006-07-06
EP1408960A1 (en) 2004-04-21
US20040138246A1 (en) 2004-07-15
JP4862120B2 (ja) 2012-01-25
US20070161669A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
DE60223544D1 (de) Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung
DE60211905D1 (de) Benz-indol- und benzo-chinolin-derivate als prodrugs zur tumorbehandlung
DE60220057D1 (de) Indoline und tetrahydro-chinoline als prodrugs zur tumorbehandlung
PT2420234E (pt) 1h-benzimidazole-4-carboxamidas substituídas com um carbono quaternário na posição 2 como inibidores de parp para uso no tratamento do cancro
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
SG164368A1 (en) Treatment of cancer
WO2010003475A3 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
FR16C0021I1 (cg-RX-API-DMAC10.html)
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
EP3173415A3 (en) Activators of human pyruvate kinase
NZ580226A (en) Dimer compounds as inhibitors of iap
MX2009006864A (es) Inhibidores novedosos de c jun-n-terminal cinasas.
EP1775342A8 (en) Anticancer agent containing minus-strand rna virus
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2006035244A3 (en) Ecteinascidin compounds as anti -inflammatory agents
WO2007067813A3 (en) Methods and compositions for assessing alterations in gene expression patterns in clinically normal tissues obtained from heterozygous carriers of mutant genes associated with cancer and methods of use thereof
WO2006071966A3 (en) Rapamycin compounds in the treatment of neurofibromatosis type 1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties